SGLT2 Inhibitors and Perioperative Period

NCT06326528 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2024-03-22

No results posted yet for this study

Summary

The expanded use of SGLT2 inhibitors motivates us to assess the role of SGLT2 inhibitors in perioperative period on patients who will undergo cardiac surgery in Assiut University.

Conditions

  • Perioperative Complication

Interventions

DRUG

SGLT2 inhibitor

Dapagliflozin 10 mg or Empagliflozin 25mg

Sponsors & Collaborators

  • Assiut University

    lead OTHER

Principal Investigators

  • Salma M Taha, MD · Assiut University

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-05-01
Primary Completion
2025-04-01
Completion
2025-10-01

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06326528 on ClinicalTrials.gov